1. In Vivo
  2. >>Business Strategy

Alnylam Takes Platform Monetization to a Whole New and Non-Exclusive Level

Alnylam's monster deal with Roche for non-exclusive rights to the biotech's RNAi platform across four therapeutic areas sets the bar for technology platform monetization. Not only is Alnylam gaining $331 million in upfront payments, it can turn around and re-license those same rights at any time. Roche is for the first time making a splash in RNAi, which it and other companies are betting will be a new therapeutic modality.

$331 million in up-front payments—and potentially much more to boot—has bought Roche access to a small but decidedly non-exclusive club.

In a broad deal with Alnylam Pharmaceuticals Inc. valued by the companies potentially in excess of $1 billion, Roche is gaining non-exclusive rights to Alnylam’s existing RNA interference IP in oncology, respiratory diseases, metabolic diseases, and certain non-viral liver diseases. [See Deal] The companies will also eventually work together on one or more as-yet-undeclared disease targets within those areas

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business Strategy

Is Advanced AI Revolutionizing Sales Enablement In Pharma?

 
• By Marina Hickson

Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.

Laying The Foundation And Overcoming Prerequisites To Establish AI Within Health Care

 
• By Mike King

As the health care industry undergoes a digital transformation, the integration of AI into Quality and Regulatory Management Systems is proving essential. The challenges for successful AI deployment emphasize the need for robust digital infrastructure, data literacy programs and privacy measures to enhance patient safety and commercial performance.

Aurion Biotech’s Ophthalmic Cell Therapy For The Masses

 
• By David Wild

Aurion Biotech is developing a cell therapy for corneal diseases that is cheap enough to produce and can be scaled that it should reach the masses in a way that other cell therapies cannot.

Neurodegenerative Disease Investment: Shifting Paradigms Beyond Amyloid And Tau

 
• By David Wild

Companies are exploring new mechanisms of action beyond traditional amyloid and tau and both investors and big pharma are willing to make deals when the science is compelling, panelists at Biotech Showcase said.

More from In Vivo

Protagonist’s Patel: Building A Differentiated Peptide Platform With Strategic Patience

 
• By David Wild

After revolutionizing the peptide therapeutic landscape, CEO Dinesh Patel reflects on the journey from surviving the 2008 financial crisis to developing a platform now poised to deliver back-to-back blockbuster approvals.

With 75 Pipeline Candidates, TIL Therapies Gain Momentum in Solid Tumor Space

 
• By David Wild

Tumor infiltrating lymphocyte therapies show promise for solid tumors, with a first FDA approval, but face manufacturing and access challenges as development continues.

NewAmsterdam’s Davidson On Reviving “Failed” Drug Class To Fill Cardiovascular Treatment Gap

 
• By David Wild

After a string of high-profile failures by big pharma, Michael Davidson is positioning his company's CETP inhibitor as the next breakthrough in cardiovascular medicine. The body of data to support this position is growing.